ReNetX Bio Receives Fast Track Designation From U.S. FDA
January 08, 2020 09:02 ET
|
ReNetx Bio
NEW HAVEN, Conn., Jan. 08, 2020 (GLOBE NEWSWIRE) -- ReNetX Bio announced today that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track Designation for ReNetX Bio’s...
ReNetX Bio Announces Initiation of Patient Dosing in the First Phase 1 Clinical Trial of Fusion Protein AXER-204
August 14, 2019 09:02 ET
|
ReNetx Bio
NEW HAVEN, Conn., Aug. 14, 2019 (GLOBE NEWSWIRE) -- ReNetX Bio, Inc., a leading biotechnology company committed to reversing disease and damage for patients suffering from central nervous system...
ReNetX Bio Invited to Present Breakthrough at Leading Spinal Cord Injury Symposium
April 10, 2018 08:00 ET
|
ReNetx Bio
NEW HAVEN, Conn., April 10, 2018 (GLOBE NEWSWIRE) -- Thanks to the promise of its NoGo Trap therapeutic for treating chronic spinal cord injury (SCI), New Haven-based startup ReNetX Bio has been...
Remedy Pharmaceuticals Co-founder and CEO Brings Clinical Trial and Company-Building Experience to ReNetX Bio Advisory Board
February 12, 2018 10:00 ET
|
ReNetX Bio
NEW HAVEN, Conn., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Sven Jacobson will be the first to admit that developing a new therapeutic for spinal cord injury is a challenging road. But the latest member of...
ReNetX Bio Receives $7M Commitment from Wings for Life to Bring Spinal Cord Treatment to Trial
November 07, 2017 13:00 ET
|
ReNetx Bio
NEW HAVEN, Conn., Nov. 07, 2017 (GLOBE NEWSWIRE) -- The Wings for Life foundation has made a significant commitment to ReNetX Bio, a New-Haven, Conn. based biotech startup that is advancing a...
Leading Spinal Cord Injury Experts Join ReNetX Scientific Advisory Board
October 10, 2017 14:15 ET
|
ReNetx Bio
NEW HAVEN, Conn., Oct. 10, 2017 (GLOBE NEWSWIRE) -- ReNetX Bio, a company developing first-in-class therapeutics to treat injury to the central nervous system, is expanding its Scientific Advisory...